Search results for " DIABETES MELLITUS"

showing 10 items of 309 documents

Effects of Liraglutide on Metabolic Parameters and Carotid Intima-Media Thickness in Patients with The Metabolic Syndrome: A 12-Month Prospective Pil…

2014

Recent research indicates that therapy with the GLP-1 agonist liraglutide in patients with type 2 diabetes mellitus (T2DM) seems to have beneficial actions on blood pressure, lipids, and the atherosclerotic process, which may be independent of its effect on glucose metabolism. However, the effects of liraglutide in subjects with the metabolic syndrome (MetS) are largely unknown. Forty-nine subjects with the MetS (24 men and 25 women, age 65±10 yrs) diagnosed by the AHA/NHLBI criteria were included in a 12-month prospective study. All subjects had T2DM, were naïve to incretin-based therapies, and treated with metformin only. Liraglutide was added at a dose of 0.6 mg subcutaneously daily for …

Liraglutide the metabolic syndrome type 2 diabetes mellitus
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct

Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic …

2020

Abstract Background and aim Increased intestinal permeability plays a key role in the pathogenesis of fat deposition in the liver. The aim of our study was to assess whether a single nucleotide polymorphism of protein tyrosine phosphatase non-receptor type 2 (PTPN2) (rs2542151 T→G), involved in intestinal permeability, may be associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods and results We recruited a prospective cohort of NAFLD subjects and matched controls. Clinical data, PTPN2 genotype and laboratory data were collected for each patient. Results were stratified according to liver histology and diabetes. We enrolled 566 cases and 377 co…

Liver CirrhosisMaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologySeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasePrevalenceProspective StudiesProtein Tyrosine Phosphatase Non-Receptor Type 2Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedPhenotypeItalyLiver biopsyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismIntestinal permeabilityPolymorphism Single NucleotideRisk AssessmentPermeability03 medical and health sciencesInternal medicineDiabetes mellitusmedicineGenetic susceptibilityHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic Association Studiesbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 2Intestinal AbsorptionCase-Control StudiesSteatosisSteatohepatitisbusiness
researchProduct

MAGNESIUM METABOLISM IN TYPE 2 DIABETES MELLITUS, METABOLIC SYNDROME AND INSULIN RESISTANCE.

2007

MAGNESIUM METABOLISM DIABETES MELLITUS.
researchProduct

Genetic systems for a new approach to risk of progression of diabetic retinopathy.

2016

OBJECTIVE: To evaluate the risk of progression of diabetic retinopathy (DR) using new strategies to obtain genetic information in type 2 diabetes (T2D) based on interfering ribonucleic acid (RNA). MATERIAL AND METHODS: A prospective multicentre case-control study of 132 participants was distributed into: T2D with (+DR) or without (-DR) (T2DG; n=77), and a control group (CG; n=55). After an eye examination and personal interview, tears were collected for molecular analysis (expression of microRNAs [miRNAs] (miRCURY ARN Isolation Kit, Qiagen)]. Libraries, 137 vs. 140bp (GeneMapper, Applied Biosystems), were obtained in 18 samples (T2DG+DR=6; T2DG-DR=6; CG=6) by performing next-generation sequ…

Male0301 basic medicineOncologyMicro RNAsmedicine.medical_specialtyBiomarcadores preclinicosType 2 diabetesMicro-ARNBioinformaticsRisk AssessmentInterference by RNA03 medical and health sciencesDiabetic retinopathyInternal medicineType 2 diabetes mellitusmedicineHumansProspective StudiesFamily historyAgedDiabetic Retinopathymedicine.diagnostic_testSequence Analysis RNAbusiness.industryPre-clinical biomarkersType 2 Diabetes MellitusGenetic systemsRetinopatia diabeticaGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseInterferencia por ARNMolecular analysisDiabetes mellitus tipo 2030104 developmental biologyDiabetes Mellitus Type 2Eye examinationCase-Control StudiesDisease ProgressionTearsFemalebusinessBiomarcadores preclínicos Diabetes mellitus tipo 2 Diabetic retinopathy Interference by RNA Interferencia por ARN Micro RNAs Micro-ARN Pre-clinical biomarkers Retinopatía diabética Type 2 diabetes mellitus
researchProduct

Lipidomic profiling identifies signatures of metabolic risk

2020

Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. Results: Thirty-nine lipids were…

Male0301 basic medicineResearch paperdhSL dihydrosphingolipidBMI body mass indexlcsh:MedicineATHEROGENIC LIPOPROTEINSBioinformaticsFHS Framingham Heart StudyPC phosphatidylcholinePESA Progression of Early Subclinical Atherosclerosis0302 clinical medicineFramingham Heart StudyRisk FactorsSAFHS San Antonio Family Heart StudyLC-MS/MS liquid chromatography-tandem mass spectrometryMedicineLongitudinal StudiesMetabolic riskPLASMA SPHINGOLIPID METABOLISMPOPULATIONlcsh:R5-920education.field_of_studySPHINGOMYELINCE cholesteryl esterDysglycemiaGeneral MedicineMiddle AgedLipidomePS phosphatidylserineCardiovascular diseaseLipidsMetabolic syndrome3. Good healthCARDIOVASCULAR-DISEASE030220 oncology & carcinogenesisHEARTMetS metabolic syndromeFemaleDisease SusceptibilityLGPL lysoglycerophospholipidSL sphingolipidlcsh:Medicine (General)LPE lysophosphatidylethanolamineAdultFDR false discovery rateTAG triacylglycerolPopulationCer ceramideCVD cardiovascular diseasePE phosphatidylethanolamineDENSITY-LIPOPROTEINRisk AssessmentGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsHumanseducationT2DM type II diabetes mellitusAgedLPC lysophosphatidylcholineSM sphingomyelinbusiness.industryCERAMIDElcsh:RHDL-C High density lipoprotein cholesterolBiomarkerLipid Metabolismmedicine.diseaseObesitySphingolipidCross-Sectional Studies030104 developmental biologyDyslipidemiaERF Erasmus Family StudyLipidomicsMetabolic syndromeINDUCED INSULIN-RESISTANCEbusinessDAG diacylglycerolBody mass indexBiomarkersDyslipidemiaMRM multiple reaction monitoringFASTING GLUCOSE
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

Changes of arterial hemodynamics in patients with type 2 diabetes mellitus or impaired glucose tolerance

2006

Aim: The aim of our study was to evaluate the arterial hemodynamics in patients with type 2 diabetes mellitus or impaired glucose tolerance without clinical or Doppler evidence of peripheral arterial disease, in order to early detect vascular damage. Methods. We studied 20 subjects (12 men and 8 women, aged between 48 and 62 years) with type 2 diabetes mellitus (Group 1), 20 subjects (11 men and 9 women, aged between 49 and 61 years) with reduced glucose tolerance (Group 2), and 20 normal subjects (10 men and 10 women, aged between 48 and 62 years) (Group 3). Each subject underwent strain-gauge plethysmography and the following parameters were evaluated: rest flow (RF); peak flow (PF); PF/R…

MaleAnalysis of Variancearterial hemodynamics type 2 diabetes mellitus impaired glucose toleranceArtery Haemodynamics Diabetes mellitus Impaired glucose tolerance Strain-gauge plethysmographyBlood PressureHyperemiaArteriesMiddle AgedDiabetes Mellitus Type 2Lower ExtremityIschemiaRegional Blood FlowCase-Control StudiesGlucose IntoleranceHumansFemaleVascular Resistance
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct